Research has found that tumor growth is significantly slowed by the use of NLRP3 antagonists or gene knockout techniques, accompanied by a substantial decrease in inflammatory factors (Tezcan et al., 2021; Xue et al., 2019). This evidence concerns the gene NLRP3 and neoplasm.